ReviewIJID regions2025
Febrile neutropenia in the Middle East and North Africa Region: trends, management, and outcomes (2000-2024)-A systematic review.
Review in IJID regions, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Epidemiology of oncologic emergency in Ethiopia: a systematic review and meta-analysis.BMC emergency medicine · 2025Pooled it
- Enhanced detection of sepsis pathogens in hospitalized febrile neutropenia patients using blood culture broths with TaqMan array card.Research square · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Febrile neutropenia (FN) is a serious complication of chemotherapy, especially in hematologic malignancies, and carries significant risk of morbidity and mortality risks. Infections, often originating from endogenous flora, are common, with gram-positive and gram-negative bacteria being the predominant pathogens. This systematic review, registered in PROSPERO (ID: CRD420241008055) examines FN incidence, characteristics, infections, and treatment outcomes in the Middle East and North Africa. A total of 22 studies from nine countries, covering 2864 patients and 3245 FN episodes, were included. Bloodstream infections were the most common source, with gram-negative pathogens more prevalent in solid tumors and gram-positive in hematologic malignancies. Empirical antibiotic choices varied significantly across countries, with piperacillin-tazobactam being the most commonly used. However, antimicrobial resistance, particularly from multidrug-resistant organisms, posed significant challenges. Mortality rates reached 12.5%, influenced by healthcare access and antimicrobial resistance. The findings highlight regional disparities in FN management and emphasize the need for tailored antimicrobial stewardship programs, rapid diagnostics, and standardized treatment protocols to improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.